



Title: Pre-Exposure Prophylaxis (PrEP) for Human Immunodeficiency Virus (HIV) Prevention - NCD 210.15

Decision: The Centers for Medicare & Medicaid Services (CMS) has determined that the evidence is sufficient to cover drugs used for Pre-Exposure Prophylaxis (PrEP) for beneficiaries with risk of HIV infection for the treatment of HIV prophylaxis.

What this means: Medicare benefits now include coverage of drugs used for Pre-Exposure Prophylaxis (PrEP) services if required components for PrEP are met. Requirements are outlined in the National Coverage Determination (see the link below).

Effective: 09/30/2024

For more information, call Customer Service at the phone number on the back of your member ID card.

You can find the announcement at

<https://www.cms.gov/files/document/prep-hiv-prevention.pdf>

H2456_H5937_Y0120_14634_102024_C

U14634 (10/2024)

Toll free 1-800-203-7225, TTY 1-800-688-2534

Attention. If you need free help interpreting this document, call the above number.

Thov ua twb zoo nyeem. Yog hais tias koj xav tau kev pab txhais lus rau tsab ntaub ntawv no pub dawb, ces hu rau tus najnpawb xov tooj saum toj no.

Digniin. Haddii aad u baahantahay caawimaad lacag-la'aan ah ee tarjumaadda (afcelinta) qoraalkan, lambarka kore wac.

Atención. Si desea recibir asistencia gratuita para interpretar este documento, llame al número indicado arriba.



No English?

**1-800-203-7225
1-800-688-2534 (TTY)**

Discrimination is against the law. UCare does not discriminate because of race, color, national origin, creed, religion, sexual orientation, public assistance status, marital status, age, disability or sex.